What is⁤ RSV and Why is it a Concern for Seniors?

Respiratory Syncytial Virus (RSV) is ‍a common respiratory virus that usually causes mild,cold-like ⁣symptoms. However, for older adults, RSV can lead ‍to serious⁢ complications like pneumonia and bronchitis, exacerbating ⁢existing conditions like COPD and⁣ heart failure. ⁤According to the⁤ CDC,⁣ RSV is responsible for approximately 60,000-160,000 ⁤hospitalizations and 6,000-10,000⁤ deaths among adults⁤ 65 years and older each year in the United States.

Prior to the vaccine, treatment for RSV was largely supportive, focusing on managing symptoms.There was no ⁣specific antiviral therapy widely available. This‍ made⁤ prevention, through measures like handwashing and avoiding close contact with sick individuals, particularly important.

The New RSV Vaccines:⁢ How They Work

Two RSV vaccines have been approved by the FDA: Arexvy (GSK) and Abrysvo (Pfizer). Both vaccines utilize different technologies to stimulate an⁤ immune response. Arexvy is a recombinant subunit ‍vaccine,meaning it contains a specific protein from the RSV virus. Abrysvo uses mRNA technology,⁢ similar to some COVID-19 vaccines,⁢ to instruct cells to produce⁤ the⁤ viral protein.

Clinical trials have demonstrated a high degree of ⁢efficacy. For exmaple, the PROTECT trial of Abrysvo ⁤showed approximately 82.6%⁢ efficacy in preventing RSV-associated lower respiratory tract disease (LRTD) in adults aged 60 years and older. Arexvy demonstrated around 82.6% efficacy in preventing RSV-associated ⁣LRTD with medical attendance.

Who ‍Shoudl⁤ Get ‍Vaccinated?

The CDC recommends that adults aged 60 years and older may receive an RSV vaccine, based on shared ⁣clinical decision-making with ‍their healthcare provider. This means a discussion ⁣about⁣ individual risk factors, potential benefits, and any concerns is crucial. Factors to consider ‍include overall health status, underlying medical conditions, and lifestyle.